https://doi.org/10.4081/monaldi.2022.2146
Management of bronchial asthma in 2021
Submitted: November 8, 2021
Accepted: January 30, 2022
Published: February 22, 2022
Accepted: January 30, 2022
Abstract Views: 1179
PDF: 514
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
To The Editor,
The Global Initiative for Asthma (GINA) 2021 update was published on the 28th of April, 2021. There are significant changes, including treatment of mild asthma, the role of azithromycin, treatment of asthma in COVID-19 times, and role of biologics...
Global Initiative for Asthma. Global strategy for asthma management and prevention (updated 2021). Accessed on: 8 Nov 2021. Available from: https://ginasthma.org/wp-content/uploads/2021/04/GINA-2021-Main-Report_FINAL_21_04_28-WMS.pdf
Ish P, Malhotra N, Gupta N. GINA 2020: what's new and why? J Asthma 2021;58:1273-7.
DOI: https://doi.org/10.1080/02770903.2020.1788076
O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide- formoterol as needed in mild asthma. N Engl J Med. 2018;378:1865-76.
DOI: https://doi.org/10.1056/NEJMoa1715274
Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide- formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018;378:1877-87.
DOI: https://doi.org/10.1056/NEJMoa1715275
Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide formoterol as needed for mild asthma. N Engl J Med 2019;380:2020-30.
DOI: https://doi.org/10.1056/NEJMoa1901963
Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, openlabel, multicentre, superiority, randomised controlled trial. Lancet 2019;394:919-98.
DOI: https://doi.org/10.1016/S0140-6736(19)31948-8
Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J 2020;55:1901872.
DOI: https://doi.org/10.1183/13993003.01872-2019
Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet 2019;394:1737-49.
DOI: https://doi.org/10.1016/S0140-6736(19)32215-9
Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med 2021;9:69-84.
DOI: https://doi.org/10.1016/S2213-2600(20)30389-1
Lugogo NL, Kreindler JL, Martin UJ, et al. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. Ann Allergy Asthma Immunol 2020;125:171-6.
DOI: https://doi.org/10.1016/j.anai.2020.04.011
Humbert M, Taille C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J 2018;51:1702523.
DOI: https://doi.org/10.1183/13993003.02523-2017
Hiles SA, McDonald VM, Guilhermino M, et al. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. Eur Respir J 2019;54:1901381.
DOI: https://doi.org/10.1183/13993003.01381-2019
Lazarinis N, Jørgensen L, Ekström T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax 2014;69:130-6.
DOI: https://doi.org/10.1136/thoraxjnl-2013-203557
14. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med 2021;9:149-58.
DOI: https://doi.org/10.1016/S2213-2600(20)30416-1
Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: A systematic review and meta-analysis. JAMA 2018;319:1485-96.
DOI: https://doi.org/10.1001/jama.2018.2769
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430-6.
DOI: https://doi.org/10.1038/s41586-020-2521-4
Liu S, Cao Y, Du T, Zhi Y. Prevalence of comorbid asthma and related outcomes in COVID-19: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2021;9:693-701.
DOI: https://doi.org/10.1016/j.jaip.2020.11.054
How to Cite
Gupta, Nitesh, Nipun Malhotra, Shekhar Kunal, and Pranav Ish. 2022. “Management of Bronchial Asthma in 2021”. Monaldi Archives for Chest Disease 92 (4). https://doi.org/10.4081/monaldi.2022.2146.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- M. Bussotti, S. Di Marco, G. Marchese, P.G. Agostoni, Subclinical pulmonary edema in endurance athletes , Monaldi Archives for Chest Disease: Vol. 77 No. 2 (2012): Pulmonary series
- L. Proietti, L. Spicuzza, A. Di Maria, R. Polosa, E. Sebastian Torres, V. Asero, G.U. Di Maria, Non-occupational malignant pleural mesothelioma due to asbestos and non-asbestos fibres , Monaldi Archives for Chest Disease: Vol. 65 No. 4 (2006): Pulmonary series
- R.A. Stolarek, M. Kasielski, J. Rysz, P. Bialasiewicz, D. Nowak, Differential effect of cigarette smoking on hydrogen peroxide and thiobarbituric acid reactive substances exhaled in patients with community acquired pneumonia , Monaldi Archives for Chest Disease: Vol. 65 No. 1 (2006): Pulmonary series
- B. Chakrabarti, P.D.O. Davies, Pleural tuberculosis , Monaldi Archives for Chest Disease: Vol. 65 No. 1 (2006): Pulmonary series
- G. Ciprandi, G.L. Marseglia, M.A. Tosca, Allergen-specific immunotherapy: an update on immunological mechanisms of action , Monaldi Archives for Chest Disease: Vol. 65 No. 1 (2006): Pulmonary series
- C. Incorvaia, F. Frati, P. Puccinelli, G.G. Riario-Sforza, S. Dal Bo, Dose dependence of efficacy and safety of subcutaneous immunotherapy , Monaldi Archives for Chest Disease: Vol. 65 No. 1 (2006): Pulmonary series
- D. Eleftheriou, S. Katsenos, S. Zorbas, I. Griveas, K. Psathakis, Pulmonary fibrosis presenting as an early manifestation of microscopic polyangiitis , Monaldi Archives for Chest Disease: Vol. 77 No. 3-4 (2012): Pulmonary series
- Massimo F. Piepoli, Exercise Rehabilitation in Heart Disease: the real “polypill†for primary and secondary prevention , Monaldi Archives for Chest Disease: Vol. 64 No. 2 (2005): Cardiac series
- Marco Ambrosetti, Mario Salerno, Walter Ageno, Roberto Tramarin, Roberto FE Pedretti, Is physical training contraindicated in patients with deep vein thrombosis during cardiac rehabilitation? , Monaldi Archives for Chest Disease: Vol. 64 No. 1 (2005): Cardiac series
- Paolo Biagi, Luigi Abate, Heart failure, oxidative stress and allopurinol , Monaldi Archives for Chest Disease: Vol. 64 No. 1 (2005): Cardiac series
<< < 10 11 12 13 14 15 16 17 18 19 > >>
You may also start an advanced similarity search for this article.
